Share Price and Basic Stock Data
Last Updated: December 18, 2025, 12:27 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Astec Lifesciences Ltd operates in the agrochemicals sector, primarily focusing on the production of pesticides and related chemicals. The company has seen a notable decline in revenue over the past few years, with reported sales of ₹628 Cr in FY 2023, down from ₹677 Cr in FY 2022. The most recent quarterly figures indicate a continuing downward trend, with revenues dropping to ₹51 Cr in December 2023, compared to ₹127 Cr in March 2023. This pattern suggests a significant volatility in demand or operational challenges that the company is facing. A deeper dive into the quarterly performance shows fluctuations, with the highest quarterly sales recorded at ₹200 Cr in September 2022, before a stark decline in subsequent quarters. Such revenue instability raises questions about the company’s market position and its ability to maintain a steady customer base in a competitive environment.
Profitability and Efficiency Metrics
Profitability has been a significant concern for Astec Lifesciences, evidenced by its negative net profit margin, which stood at -35.32% for FY 2025. The company reported a net profit of -₹135 Cr for the same period, a stark contrast to the ₹90 Cr profit recorded in FY 2022. Operating profit margins have also turned negative, with an operating profit margin (OPM) of -17% in FY 2025, down from a healthy 23% in FY 2022. The interest coverage ratio is another red flag, currently at -1.65x, indicating that the company is struggling to cover its interest expenses, which rose significantly to ₹37 Cr in FY 2025. These figures highlight a critical need for Astec to reassess its cost structure and operational efficiencies to regain profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Astec Lifesciences presents a mixed picture. On one hand, the company has reported total borrowings of ₹555 Cr as of FY 2025, a significant increase from ₹341 Cr in FY 2023. This rising debt level raises concerns about financial leverage and the sustainability of its capital structure, especially with a total equity capital of ₹20 Cr. The current ratio is slightly below the comfort zone at 0.93x, suggesting potential liquidity issues. However, the book value per share has seen a decline, standing at ₹119.70 for FY 2025, down from ₹214 in FY 2023. This indicates a decrease in shareholder equity, which can be alarming for current and prospective investors. The company’s return on equity (ROE) of -57.40% further underscores the challenges in generating shareholder value amidst these financial strains.
Shareholding Pattern and Investor Confidence
Astec Lifesciences’ shareholding pattern reveals a strong promoter backing, with promoters holding 72.42% of the company as of September 2025. This level of control can be seen as a stabilizing factor, as it suggests a commitment from the founders to steer the company through turbulent times. However, the absence of foreign institutional investors (FIIs) and a mere 4.01% stake from domestic institutional investors (DIIs) reflect a lack of confidence from major institutional players, which could indicate concerns over the company’s financial health. The public shareholding stands at 23.57%, a slight decline from previous periods, which may point to diminishing retail investor interest. The number of shareholders has also fallen to 18,276, suggesting a potential exit of investors in light of deteriorating financial performance.
Outlook, Risks, and Final Insight
Looking ahead, Astec Lifesciences faces several risks that could impact its recovery and growth trajectory. The persistent decline in revenue and profitability metrics is a significant concern, which could lead to further erosion of investor confidence. The rising debt levels may limit operational flexibility and increase financial risk, especially if market conditions do not improve. Additionally, the company’s negative interest coverage ratio raises alarms about its ability to service debt, which could lead to liquidity challenges. On the flip side, the strong promoter holding could provide necessary support and strategic direction, potentially stabilizing the company in the long run. Investors may want to monitor operational improvements and market demand closely, as these factors will be critical in determining whether Astec Lifesciences can turn its fortunes around. The current financial landscape suggests caution, and while there may be potential for recovery, significant challenges remain that could impact future performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Epigral Ltd | 6,048 Cr. | 1,401 | 2,114/1,398 | 15.0 | 487 | 0.43 % | 24.9 % | 22.3 % | 10.0 |
| Dharmaj Crop Guard Ltd | 843 Cr. | 249 | 391/165 | 17.3 | 131 | 0.00 % | 12.0 % | 9.28 % | 10.0 |
| Bhaskar Agrochemicals Ltd | 62.8 Cr. | 121 | 149/56.6 | 11.3 | 40.0 | 0.00 % | 21.3 % | 24.7 % | 10.0 |
| Bhagiradha Chemicals & Industries Ltd | 2,958 Cr. | 228 | 333/222 | 112 | 54.9 | 0.07 % | 7.44 % | 4.91 % | 1.00 |
| Best Agrolife Ltd | 942 Cr. | 398 | 670/244 | 73.6 | 342 | 0.75 % | 12.9 % | 9.95 % | 10.0 |
| Industry Average | 10,840.20 Cr | 1,121.63 | 32.02 | 382.34 | 0.44% | 15.21% | 19.87% | 7.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 184 | 200 | 117 | 127 | 143 | 111 | 51 | 154 | 69 | 99 | 94 | 120 | 91 |
| Expenses | 159 | 166 | 105 | 122 | 140 | 114 | 69 | 141 | 116 | 118 | 100 | 114 | 102 |
| Operating Profit | 25 | 33 | 12 | 5 | 3 | -3 | -18 | 13 | -46 | -20 | -6 | 6 | -11 |
| OPM % | 14% | 17% | 10% | 4% | 2% | -3% | -36% | 8% | -67% | -20% | -6% | 5% | -12% |
| Other Income | 3 | 4 | 4 | 3 | 2 | 1 | 1 | 2 | 1 | 2 | 2 | 1 | 1 |
| Interest | 4 | 5 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 9 | 10 | 10 | 11 |
| Depreciation | 9 | 8 | 9 | 8 | 9 | 9 | 9 | 9 | 9 | 11 | 11 | 12 | 11 |
| Profit before tax | 15 | 25 | 1 | -6 | -11 | -18 | -32 | -1 | -62 | -39 | -25 | -16 | -33 |
| Tax % | 25% | 25% | 31% | -20% | -26% | -24% | -24% | 4% | -36% | 0% | 61% | 3% | 0% |
| Net Profit | 11 | 18 | 1 | -5 | -8 | -13 | -24 | -1 | -40 | -39 | -40 | -16 | -33 |
| EPS in Rs | 5.09 | 8.17 | 0.38 | -2.22 | -3.66 | -6.00 | -10.86 | -0.43 | -17.73 | -17.21 | -18.03 | -7.18 | -14.75 |
Last Updated: August 1, 2025, 11:55 pm
Below is a detailed analysis of the quarterly data for Astec Lifesciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 91.00 Cr.. The value appears to be declining and may need further review. It has decreased from 120.00 Cr. (Mar 2025) to 91.00 Cr., marking a decrease of 29.00 Cr..
- For Expenses, as of Jun 2025, the value is 102.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 114.00 Cr. (Mar 2025) to 102.00 Cr., marking a decrease of 12.00 Cr..
- For Operating Profit, as of Jun 2025, the value is -11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6.00 Cr. (Mar 2025) to -11.00 Cr., marking a decrease of 17.00 Cr..
- For OPM %, as of Jun 2025, the value is -12.00%. The value appears to be declining and may need further review. It has decreased from 5.00% (Mar 2025) to -12.00%, marking a decrease of 17.00%.
- For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Interest, as of Jun 2025, the value is 11.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 11.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 12.00 Cr. (Mar 2025) to 11.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -33.00 Cr.. The value appears to be declining and may need further review. It has decreased from -16.00 Cr. (Mar 2025) to -33.00 Cr., marking a decrease of 17.00 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 3.00% (Mar 2025) to 0.00%, marking a decrease of 3.00%.
- For Net Profit, as of Jun 2025, the value is -33.00 Cr.. The value appears to be declining and may need further review. It has decreased from -16.00 Cr. (Mar 2025) to -33.00 Cr., marking a decrease of 17.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -14.75. The value appears to be declining and may need further review. It has decreased from -7.18 (Mar 2025) to -14.75, marking a decrease of 7.57.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:37 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 207 | 267 | 233 | 299 | 368 | 431 | 523 | 555 | 677 | 628 | 458 | 381 | 378 |
| Expenses | 171 | 213 | 201 | 236 | 299 | 354 | 437 | 443 | 522 | 551 | 464 | 448 | 396 |
| Operating Profit | 35 | 54 | 32 | 63 | 69 | 76 | 85 | 112 | 154 | 77 | -6 | -66 | -18 |
| OPM % | 17% | 20% | 14% | 21% | 19% | 18% | 16% | 20% | 23% | 12% | -1% | -17% | -5% |
| Other Income | -0 | -16 | 4 | -8 | 12 | 11 | 12 | 8 | 10 | 13 | 6 | 6 | 4 |
| Interest | 9 | 13 | 13 | 12 | 11 | 12 | 13 | 5 | 9 | 21 | 25 | 37 | 40 |
| Depreciation | 15 | 13 | 10 | 14 | 15 | 19 | 23 | 26 | 34 | 34 | 36 | 44 | 45 |
| Profit before tax | 11 | 13 | 12 | 29 | 56 | 56 | 61 | 89 | 121 | 35 | -62 | -141 | -98 |
| Tax % | 22% | -17% | 59% | 33% | 37% | 36% | 23% | 27% | 26% | 27% | -24% | -4% | |
| Net Profit | 9 | 15 | 5 | 19 | 35 | 36 | 48 | 65 | 90 | 26 | -47 | -135 | -114 |
| EPS in Rs | 4.09 | 6.66 | 2.24 | 8.57 | 15.65 | 16.03 | 21.21 | 29.04 | 40.12 | 11.41 | -20.95 | -60.16 | -50.92 |
| Dividend Payout % | 21% | 16% | 0% | 15% | 8% | 8% | 6% | 5% | 3% | 12% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 66.67% | -66.67% | 280.00% | 84.21% | 2.86% | 33.33% | 35.42% | 38.46% | -71.11% | -280.77% | -187.23% |
| Change in YoY Net Profit Growth (%) | 0.00% | -133.33% | 346.67% | -195.79% | -81.35% | 30.48% | 2.08% | 3.04% | -109.57% | -209.66% | 93.54% |
Astec Lifesciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -6% |
| 3 Years: | -17% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -63% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | -7% |
| 3 Years: | -23% |
| 1 Year: | -29% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 0% |
| 3 Years: | -14% |
| Last Year: | -45% |
Last Updated: September 4, 2025, 11:55 pm
Balance Sheet
Last Updated: December 4, 2025, 12:59 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 19 | 19 | 19 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 22 |
| Reserves | 95 | 116 | 99 | 119 | 150 | 183 | 227 | 290 | 377 | 400 | 350 | 215 | 392 |
| Borrowings | 83 | 93 | 127 | 127 | 125 | 176 | 99 | 187 | 279 | 341 | 494 | 555 | 367 |
| Other Liabilities | 88 | 133 | 85 | 69 | 119 | 83 | 226 | 181 | 221 | 219 | 112 | 92 | 102 |
| Total Liabilities | 284 | 362 | 330 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 975 | 881 | 883 |
| Fixed Assets | 132 | 133 | 95 | 103 | 115 | 167 | 194 | 213 | 340 | 318 | 386 | 499 | 500 |
| CWIP | 6 | 12 | 20 | 8 | 42 | 19 | 24 | 116 | 23 | 127 | 165 | 21 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 146 | 216 | 215 | 223 | 256 | 275 | 354 | 349 | 534 | 534 | 424 | 361 | 383 |
| Total Assets | 284 | 362 | 330 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 975 | 881 | 883 |
Below is a detailed analysis of the balance sheet data for Astec Lifesciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 22.00 Cr.. The value appears strong and on an upward trend. It has increased from 20.00 Cr. (Mar 2025) to 22.00 Cr., marking an increase of 2.00 Cr..
- For Reserves, as of Sep 2025, the value is 392.00 Cr.. The value appears strong and on an upward trend. It has increased from 215.00 Cr. (Mar 2025) to 392.00 Cr., marking an increase of 177.00 Cr..
- For Borrowings, as of Sep 2025, the value is 367.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 555.00 Cr. (Mar 2025) to 367.00 Cr., marking a decrease of 188.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 102.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 92.00 Cr. (Mar 2025) to 102.00 Cr., marking an increase of 10.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 883.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 881.00 Cr. (Mar 2025) to 883.00 Cr., marking an increase of 2.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 500.00 Cr.. The value appears strong and on an upward trend. It has increased from 499.00 Cr. (Mar 2025) to 500.00 Cr., marking an increase of 1.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 21.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 21.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 383.00 Cr.. The value appears strong and on an upward trend. It has increased from 361.00 Cr. (Mar 2025) to 383.00 Cr., marking an increase of 22.00 Cr..
- For Total Assets, as of Sep 2025, the value is 883.00 Cr.. The value appears strong and on an upward trend. It has increased from 881.00 Cr. (Mar 2025) to 883.00 Cr., marking an increase of 2.00 Cr..
Notably, the Reserves (392.00 Cr.) exceed the Borrowings (367.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -48.00 | -39.00 | -95.00 | -64.00 | -56.00 | -100.00 | -14.00 | -75.00 | -125.00 | -264.00 | -500.00 | -621.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 91 | 142 | 126 | 135 | 122 | 103 | 112 | 123 | 148 | 90 | 135 | 141 |
| Inventory Days | 192 | 147 | 177 | 133 | 122 | 121 | 131 | 113 | 176 | 268 | 224 | 196 |
| Days Payable | 114 | 179 | 169 | 116 | 155 | 83 | 218 | 137 | 179 | 161 | 102 | 100 |
| Cash Conversion Cycle | 168 | 109 | 134 | 152 | 89 | 142 | 25 | 100 | 145 | 197 | 256 | 237 |
| Working Capital Days | 23 | 19 | -28 | 1 | -8 | -2 | 8 | 4 | 12 | -17 | -1 | -26 |
| ROCE % | 11% | 20% | 12% | 20% | 22% | 20% | 20% | 22% | 22% | 8% | -4% | -13% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 526,867 | 0.06 | 44.15 | 468,589 | 2025-12-08 04:51:58 | 12.44% |
| ICICI Prudential Commodities Fund | 128,411 | 0.34 | 10.76 | 112,360 | 2025-12-08 04:51:58 | 14.29% |
| ICICI Prudential MidCap Fund | 18,107 | 0.02 | 1.52 | 15,844 | 2025-12-08 00:51:54 | 14.28% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -68.71 | -23.93 | 13.04 | 45.87 | 33.23 |
| Diluted EPS (Rs.) | -68.71 | -23.93 | 13.04 | 45.85 | 33.21 |
| Cash EPS (Rs.) | -46.40 | -5.42 | 30.22 | 63.39 | 46.32 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 119.70 | 188.44 | 214.00 | 202.40 | 157.91 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 119.70 | 188.44 | 214.00 | 202.40 | 157.91 |
| Revenue From Operations / Share (Rs.) | 194.43 | 233.66 | 320.40 | 345.23 | 283.28 |
| PBDIT / Share (Rs.) | -30.89 | -0.13 | 45.56 | 83.96 | 61.00 |
| PBIT / Share (Rs.) | -53.18 | -18.62 | 28.39 | 66.43 | 47.90 |
| PBT / Share (Rs.) | -71.89 | -31.49 | 17.82 | 61.81 | 45.47 |
| Net Profit / Share (Rs.) | -68.69 | -23.91 | 13.05 | 45.86 | 33.22 |
| NP After MI And SOA / Share (Rs.) | -68.71 | -23.93 | 13.04 | 45.85 | 33.21 |
| PBDIT Margin (%) | -15.88 | -0.05 | 14.21 | 24.31 | 21.53 |
| PBIT Margin (%) | -27.35 | -7.97 | 8.86 | 19.24 | 16.90 |
| PBT Margin (%) | -36.97 | -13.47 | 5.56 | 17.90 | 16.05 |
| Net Profit Margin (%) | -35.32 | -10.23 | 4.07 | 13.28 | 11.72 |
| NP After MI And SOA Margin (%) | -35.33 | -10.24 | 4.06 | 13.28 | 11.72 |
| Return on Networth / Equity (%) | -57.40 | -12.70 | 6.09 | 22.66 | 21.03 |
| Return on Capital Employeed (%) | -20.22 | -6.32 | 12.28 | 32.05 | 26.40 |
| Return On Assets (%) | -15.28 | -4.81 | 2.61 | 10.02 | 9.60 |
| Long Term Debt / Equity (X) | 1.19 | 0.53 | 0.02 | 0.00 | 0.12 |
| Total Debt / Equity (X) | 2.36 | 1.34 | 0.81 | 0.70 | 0.60 |
| Asset Turnover Ratio (%) | 0.41 | 0.46 | 0.66 | 0.85 | 0.88 |
| Current Ratio (X) | 0.93 | 1.00 | 0.94 | 1.05 | 1.03 |
| Quick Ratio (X) | 0.49 | 0.51 | 0.38 | 0.67 | 0.69 |
| Inventory Turnover Ratio (X) | 1.40 | 1.30 | 1.91 | 3.04 | 3.03 |
| Dividend Payout Ratio (NP) (%) | 0.00 | -6.26 | 11.50 | 3.26 | 4.51 |
| Dividend Payout Ratio (CP) (%) | 0.00 | -27.54 | 4.96 | 2.36 | 3.23 |
| Earning Retention Ratio (%) | 0.00 | 106.26 | 88.50 | 96.74 | 95.49 |
| Cash Earning Retention Ratio (%) | 0.00 | 127.54 | 95.04 | 97.64 | 96.77 |
| Interest Coverage Ratio (X) | -1.65 | -0.01 | 4.31 | 18.17 | 25.15 |
| Interest Coverage Ratio (Post Tax) (X) | -2.67 | -0.85 | 2.24 | 10.92 | 14.69 |
| Enterprise Value (Cr.) | 1875.49 | 2574.29 | 3049.60 | 3711.79 | 2144.94 |
| EV / Net Operating Revenue (X) | 4.92 | 5.62 | 4.85 | 5.49 | 3.87 |
| EV / EBITDA (X) | -30.96 | -9580.53 | 34.14 | 22.56 | 17.95 |
| MarketCap / Net Operating Revenue (X) | 3.47 | 4.55 | 4.31 | 5.08 | 3.53 |
| Retention Ratios (%) | 0.00 | 106.26 | 88.49 | 96.73 | 95.48 |
| Price / BV (X) | 5.64 | 5.64 | 6.46 | 8.66 | 6.34 |
| Price / Net Operating Revenue (X) | 3.47 | 4.55 | 4.31 | 5.08 | 3.53 |
| EarningsYield | -0.10 | -0.02 | 0.01 | 0.02 | 0.03 |
After reviewing the key financial ratios for Astec Lifesciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -68.71. This value is below the healthy minimum of 5. It has decreased from -23.93 (Mar 24) to -68.71, marking a decrease of 44.78.
- For Diluted EPS (Rs.), as of Mar 25, the value is -68.71. This value is below the healthy minimum of 5. It has decreased from -23.93 (Mar 24) to -68.71, marking a decrease of 44.78.
- For Cash EPS (Rs.), as of Mar 25, the value is -46.40. This value is below the healthy minimum of 3. It has decreased from -5.42 (Mar 24) to -46.40, marking a decrease of 40.98.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 119.70. It has decreased from 188.44 (Mar 24) to 119.70, marking a decrease of 68.74.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 119.70. It has decreased from 188.44 (Mar 24) to 119.70, marking a decrease of 68.74.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 194.43. It has decreased from 233.66 (Mar 24) to 194.43, marking a decrease of 39.23.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -30.89. This value is below the healthy minimum of 2. It has decreased from -0.13 (Mar 24) to -30.89, marking a decrease of 30.76.
- For PBIT / Share (Rs.), as of Mar 25, the value is -53.18. This value is below the healthy minimum of 0. It has decreased from -18.62 (Mar 24) to -53.18, marking a decrease of 34.56.
- For PBT / Share (Rs.), as of Mar 25, the value is -71.89. This value is below the healthy minimum of 0. It has decreased from -31.49 (Mar 24) to -71.89, marking a decrease of 40.40.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -68.69. This value is below the healthy minimum of 2. It has decreased from -23.91 (Mar 24) to -68.69, marking a decrease of 44.78.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -68.71. This value is below the healthy minimum of 2. It has decreased from -23.93 (Mar 24) to -68.71, marking a decrease of 44.78.
- For PBDIT Margin (%), as of Mar 25, the value is -15.88. This value is below the healthy minimum of 10. It has decreased from -0.05 (Mar 24) to -15.88, marking a decrease of 15.83.
- For PBIT Margin (%), as of Mar 25, the value is -27.35. This value is below the healthy minimum of 10. It has decreased from -7.97 (Mar 24) to -27.35, marking a decrease of 19.38.
- For PBT Margin (%), as of Mar 25, the value is -36.97. This value is below the healthy minimum of 10. It has decreased from -13.47 (Mar 24) to -36.97, marking a decrease of 23.50.
- For Net Profit Margin (%), as of Mar 25, the value is -35.32. This value is below the healthy minimum of 5. It has decreased from -10.23 (Mar 24) to -35.32, marking a decrease of 25.09.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -35.33. This value is below the healthy minimum of 8. It has decreased from -10.24 (Mar 24) to -35.33, marking a decrease of 25.09.
- For Return on Networth / Equity (%), as of Mar 25, the value is -57.40. This value is below the healthy minimum of 15. It has decreased from -12.70 (Mar 24) to -57.40, marking a decrease of 44.70.
- For Return on Capital Employeed (%), as of Mar 25, the value is -20.22. This value is below the healthy minimum of 10. It has decreased from -6.32 (Mar 24) to -20.22, marking a decrease of 13.90.
- For Return On Assets (%), as of Mar 25, the value is -15.28. This value is below the healthy minimum of 5. It has decreased from -4.81 (Mar 24) to -15.28, marking a decrease of 10.47.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 1.19. This value exceeds the healthy maximum of 1. It has increased from 0.53 (Mar 24) to 1.19, marking an increase of 0.66.
- For Total Debt / Equity (X), as of Mar 25, the value is 2.36. This value exceeds the healthy maximum of 1. It has increased from 1.34 (Mar 24) to 2.36, marking an increase of 1.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.41. It has decreased from 0.46 (Mar 24) to 0.41, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 0.93. This value is below the healthy minimum of 1.5. It has decreased from 1.00 (Mar 24) to 0.93, marking a decrease of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 0.49. This value is below the healthy minimum of 1. It has decreased from 0.51 (Mar 24) to 0.49, marking a decrease of 0.02.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.40. This value is below the healthy minimum of 4. It has increased from 1.30 (Mar 24) to 1.40, marking an increase of 0.10.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has increased from -6.26 (Mar 24) to 0.00, marking an increase of 6.26.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has increased from -27.54 (Mar 24) to 0.00, marking an increase of 27.54.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 106.26 (Mar 24) to 0.00, marking a decrease of 106.26.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 127.54 (Mar 24) to 0.00, marking a decrease of 127.54.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -1.65. This value is below the healthy minimum of 3. It has decreased from -0.01 (Mar 24) to -1.65, marking a decrease of 1.64.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -2.67. This value is below the healthy minimum of 3. It has decreased from -0.85 (Mar 24) to -2.67, marking a decrease of 1.82.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,875.49. It has decreased from 2,574.29 (Mar 24) to 1,875.49, marking a decrease of 698.80.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.92. This value exceeds the healthy maximum of 3. It has decreased from 5.62 (Mar 24) to 4.92, marking a decrease of 0.70.
- For EV / EBITDA (X), as of Mar 25, the value is -30.96. This value is below the healthy minimum of 5. It has increased from -9,580.53 (Mar 24) to -30.96, marking an increase of 9,549.57.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.47. This value exceeds the healthy maximum of 3. It has decreased from 4.55 (Mar 24) to 3.47, marking a decrease of 1.08.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 106.26 (Mar 24) to 0.00, marking a decrease of 106.26.
- For Price / BV (X), as of Mar 25, the value is 5.64. This value exceeds the healthy maximum of 3. There is no change compared to the previous period (Mar 24) which recorded 5.64.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.47. This value exceeds the healthy maximum of 3. It has decreased from 4.55 (Mar 24) to 3.47, marking a decrease of 1.08.
- For EarningsYield, as of Mar 25, the value is -0.10. This value is below the healthy minimum of 5. It has decreased from -0.02 (Mar 24) to -0.10, marking a decrease of 0.08.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Astec Lifesciences Ltd:
- Net Profit Margin: -35.32%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -20.22% (Industry Average ROCE: 15.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -57.4% (Industry Average ROE: 19.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -2.67
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.49
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 32.02)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 2.36
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -35.32%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Agro Chemicals/Pesticides | Godrej One, 3rd Floor, Pirojshanagar, Mumbai Maharashtra 400079 | astecinfo@godrejastec.com http://www.godrejastec.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Nadir B Godrej | Chairman |
| Mr. Burjis N Godrej | Managing Director |
| Mr. Balram Singh Yadav | Non Executive Director |
| Mr. Ashok V Hiremath | Non Executive Director |
| Dr. Ganapati Yadav | Independent Director |
| Mr. R R Govindan | Independent Director |
| Mr. Nandkumar Dhekne | Independent Director |
| Ms. Anjali Gupte | Independent Director |
FAQ
What is the intrinsic value of Astec Lifesciences Ltd?
Astec Lifesciences Ltd's intrinsic value (as of 18 December 2025) is 1031.32 which is 45.46% higher the current market price of 709.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 1,580 Cr. market cap, FY2025-2026 high/low of 1,254/607, reserves of ₹392 Cr, and liabilities of 883 Cr.
What is the Market Cap of Astec Lifesciences Ltd?
The Market Cap of Astec Lifesciences Ltd is 1,580 Cr..
What is the current Stock Price of Astec Lifesciences Ltd as on 18 December 2025?
The current stock price of Astec Lifesciences Ltd as on 18 December 2025 is 709.
What is the High / Low of Astec Lifesciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Astec Lifesciences Ltd stocks is 1,254/607.
What is the Stock P/E of Astec Lifesciences Ltd?
The Stock P/E of Astec Lifesciences Ltd is .
What is the Book Value of Astec Lifesciences Ltd?
The Book Value of Astec Lifesciences Ltd is 186.
What is the Dividend Yield of Astec Lifesciences Ltd?
The Dividend Yield of Astec Lifesciences Ltd is 0.00 %.
What is the ROCE of Astec Lifesciences Ltd?
The ROCE of Astec Lifesciences Ltd is 12.9 %.
What is the ROE of Astec Lifesciences Ltd?
The ROE of Astec Lifesciences Ltd is 45.3 %.
What is the Face Value of Astec Lifesciences Ltd?
The Face Value of Astec Lifesciences Ltd is 10.0.